Does iron deficiency cause a reactive increase in platelet count?

Iron deficiency is well-documented to cause a secondary, reactive elevation in platelet count, known as reactive thrombocytosis. This response represents a physiologic adaptation to impaired erythropoiesis and altered bone marrow dynamics.

Clinical evidence

• Prevalence rates: Reactive thrombocytosis is highly prevalent in iron deficiency anemia (IDA), affecting approximately 20% to 35% of adult patients and up to 69% of pediatric patients.
• Resolution timeframe: This elevation is highly reversible; standard oral or intravenous iron repletion typically restores platelet counts to the normal reference range within 2 to 12 weeks.
• Thrombotic risk: While typically benign and clinically silent, severe and untreated IDA resulting in extreme reactive thrombocytosis has been linked in rare case reports to a heightened risk of arterial or venous thrombotic complications.

Mechanistic pathways

• Lineage diversion: Megakaryocytes and erythrocytes share a common megakaryocyte-erythroid progenitor (MEP). Iron restriction impairs erythropoiesis, shifting progenitor differentiation preferentially toward the megakaryocytic lineage.
• HIF-2α stabilization: Iron serves as an essential cofactor for prolyl hydroxylases that degrade hypoxia-inducible factors (HIFs). Iron deficiency stabilizes HIF-2α in megakaryocyte progenitors, directly promoting their maturation, ploidy, and platelet production.
• Erythropoietin cross-reactivity: The hypoxia induced by anemia triggers a compensatory rise in serum erythropoietin (EPO) levels. This elevated EPO can act on early bipotent progenitors, further stimulating megakaryocyte colony formation.

Bottom line

• Iron deficiency is robustly linked to reactive thrombocytosis through thrombopoietin-independent hematopoietic reprogramming and lineage diversion, which typically resolves completely within weeks to a few months of initiating iron repletion therapy.